In conclusion, taVNS ameliorates depression‐like behaviors in CUMS model rats, inhibits the hypothalamic microglia activity and increases α7nAchR expression in the hypothalamus, which in turn activates the JAK2/STAT3 signaling pathway and inhibits the NF‐κB signaling pathway. Here, CHRNA7 is linked to depressive symptom measurement.